Welcome, Guest. Please login or register.
October 19, 2017, 04:23:36 PM

Login with username, password and session length

  • Total Members: 31660
  • Latest: Boo
  • Total Posts: 720941
  • Total Topics: 58475
  • Online Today: 333
  • Online Ever: 1421
  • (August 13, 2016, 05:18:44 AM)
Users Online
Users: 6
Guests: 308
Total: 314


Welcome to the POZ Community Forums, a round-the-clock discussion area for people with HIV/AIDS, their friends/family/caregivers, and others concerned about HIV/AIDS.  Click on the links below to browse our various forums; scroll down for a glance at the most recent posts; or join in the conversation yourself by registering on the left side of this page.

Privacy Warning:  Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If you are HIV positive and disclose this in our forums, then it is almost the same thing as telling the whole world (or at least the World Wide Web). If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.

  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.

  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.

  • Forums members must behave at all times with respect and honesty. Posting guidelines, including time-out and banning policies, have been established by the moderators of these forums. Click here for “Am I Infected?” posting guidelines. Click here for posting guidelines pertaining to all other POZ community forums.

  • We ask all forums members to provide references for health/medical/scientific information they provide, when it is not a personal experience being discussed. Please provide hyperlinks with full URLs or full citations of published works not available via the Internet. Additionally, all forums members must post information which are true and correct to their knowledge.

  • Product advertisement—including links; banners; editorial content; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from POZ.

To change forums navigation language settings, click here (members only), Register now

Para cambiar sus preferencias de los foros en español, haz clic aquí (sólo miembros), Regístrate ahora

Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Roche bags rights to AC Immune Alzheimer's drug in $418 million deal  (Read 1158 times)

0 Members and 1 Guest are viewing this topic.

Offline red_Dragon888

  • Member
  • Posts: 2,840
  • Love and Be Love in Return

Subject: NATAP: Roche Alzheimers Program

Roche bags rights to AC Immune Alzheimer's drug in $418 million deal
pharmatimes World News | June 19, 2012

Roche has entered into a second licensing and research agreement with AC Immune to get access to the fellow Swiss group's ’s anti-tau antibodies for the treatment of Alzheimer’s disease and other neurodegenerative diseases.
Under the terms of the deal AC Immune will bank an undisclosed upfront payment and is eligible to receive milestone payments totalling more than 400 million Swiss francs. The Lausanne-based group is also eligible to receive royalties.
Under the multi-year collaboration, AC Immune will work in partnership with Roche's Genentech unit to identify and formulate several pre-clinical candidates. The latter will have global responsibility for development, manufacturing and commercialisation of antibodies resulting from the collaboration.
Related Links

USA boosts Alzheimer s funding as prevention trial is launched
AC Immune says that tau protein forms twisted fibres inside brain cells and build tangles "that are considered by many in the scientific community as the second major cause of Alzheimer’s disease besides amyloid beta-plaques". Chief scientific officer Andreas Muhs noted that anti-tau-antibodies have proven highly specific to misfolded tau in relevant animal models for Alzheimer’s "and are therefore well suited to be developed as a disease-modifying drug. This has significant potential".
James Sabry, Genentech’s vice president of partnering, said the addition of the anti-tau programme "to our CNS pipeline complements other approaches we are investigating, including crenezumab which we in-licensed from AC Immune in 2006". The latter is an experimental anti-amyloid antibody which is currently being evaluated in a Phase II study in Alzheimer’s patients with mild to moderate symptoms; that deal was valued at more than $300 million, excluding royalties.
In May this year, crenezumab was selected to be tested in the world’s first-ever prevention trial in healthy individuals who are genetically destined to develop Alzheimer’s disease.

Off Crystal Meth since May 13, 2013.  In recovery with 20 months clean time.


Terms of Membership for these forums

© 2017 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.